Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

Fig. 3

Hazard ratios for the treatment arm (FEC → Doc/Gem versus FEC → Doc) in various subgroups relative to disease-free survival (a) and overall survival (b). Although there was some variation in the estimate of the treatment effect of FEC → Doc/Gem, the P values in the global likelihood ratio tests were nonsignificant. Continuous predictors were evaluated at the first decile (“low”), at the median, and at the ninth decile (“high”)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us